ADC Therapeutics SA Income Tax Expense Continuing Operations
ADC Therapeutics SA (ADCT) reported Income Tax Expense Continuing Operations of -$86.00 thousand for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Income Tax
ifrs-full:IncomeTaxExpenseContinuingOperations · last filed 2023-11-07
- ADC Therapeutics SA income tax expense continuing operations for the quarter ending 2023-09-30 was -$86.00K.
- ADC Therapeutics SA income tax expense continuing operations for the quarter ending 2023-06-30 was -$6.61M.
- ADC Therapeutics SA income tax expense continuing operations for the quarter ending 2023-03-31 was -$262.00K.
- ADC Therapeutics SA income tax expense continuing operations for the quarter ending 2022-12-31 was $3.97M.
| Period end | Income Tax Expense Continuing Operations 3 month | Income Tax Expense Continuing Operations 6 month | Income Tax Expense Continuing Operations 9 month | Income Tax Expense Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$86.00K 6-K · filed 2023-11-07 | -$6.70M derived: sum of 2 quarters · filed 2023-11-07 | -$6.96M 6-K · filed 2023-11-07 | -$2.99M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | -$6.61M 6-K · filed 2023-08-08 | -$6.87M 6-K · filed 2023-08-08 | -$2.90M derived: sum of 3 quarters · filed 2023-08-08 | -$3.62M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$262.00K 6-K · filed 2023-05-09 | $3.71M derived: sum of 2 quarters · filed 2023-05-09 | $2.99M derived: sum of 3 quarters · filed 2023-11-07 | $2.05M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $3.97M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $3.26M derived: sum of 2 quarters · filed 2023-11-07 | $2.31M derived: sum of 3 quarters · filed 2023-11-07 | $1.14M 20-F · filed 2023-03-15 |
| 2022-09-30 | -$711.00K 6-K · filed 2023-11-07 | -$1.66M derived: sum of 2 quarters · filed 2023-11-07 | -$2.83M 6-K · filed 2023-11-07 | -$24.80M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$947.00K 6-K · filed 2023-08-08 | -$2.12M 6-K · filed 2023-08-08 | -$24.09M derived: sum of 3 quarters · filed 2023-08-08 | -$23.94M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.17M 6-K · filed 2023-05-09 | -$23.14M derived: sum of 2 quarters · filed 2023-05-09 | -$23.00M derived: sum of 3 quarters · filed 2023-05-09 | -$22.76M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$21.97M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$21.83M derived: sum of 2 quarters · filed 2023-03-15 | -$21.59M derived: sum of 3 quarters · filed 2023-03-15 | -$21.48M 20-F · filed 2023-03-15 |
| 2021-09-30 | $145.00K 6-K · filed 2022-11-08 | $385.00K derived: sum of 2 quarters · filed 2022-11-08 | $492.00K 6-K · filed 2022-11-08 | $618.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $240.00K 6-K · filed 2022-08-09 | $347.00K 6-K · filed 2022-08-09 | $473.00K derived: sum of 3 quarters · filed 2023-03-15 | $470.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $107.00K 6-K · filed 2022-05-09 | $233.00K derived: sum of 2 quarters · filed 2023-03-15 | $230.00K derived: sum of 3 quarters · filed 2023-03-15 | $334.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $126.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $123.00K derived: sum of 2 quarters · filed 2023-03-15 | $227.00K derived: sum of 3 quarters · filed 2023-03-15 | $327.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | -$3.00K 6-K · filed 2021-11-02 | $101.00K derived: sum of 2 quarters · filed 2021-11-02 | $201.00K 6-K · filed 2021-11-02 | |
| 2020-06-30 | $104.00K 6-K · filed 2021-08-03 | $204.00K 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $100.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $582.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $224.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |